Inogen (NASDAQ:INGN) Upgraded at StockNews.com

StockNews.com upgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a buy rating in a report issued on Monday.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research note on Thursday, January 30th.

Inogen Stock Down 2.2 %

Shares of NASDAQ INGN opened at $10.14 on Monday. The stock has a market cap of $241.53 million, a P/E ratio of -4.51 and a beta of 1.02. The firm’s 50-day simple moving average is $10.02 and its 200 day simple moving average is $10.22. Inogen has a fifty-two week low of $5.82 and a fifty-two week high of $13.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INGN. AlphaQuest LLC acquired a new stake in Inogen in the 4th quarter valued at about $43,000. Meeder Asset Management Inc. acquired a new stake in Inogen during the fourth quarter valued at approximately $56,000. Quarry LP bought a new stake in Inogen during the third quarter worth approximately $59,000. Ieq Capital LLC acquired a new position in Inogen in the fourth quarter worth approximately $94,000. Finally, Intech Investment Management LLC bought a new position in shares of Inogen in the fourth quarter valued at $94,000. Institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.